Martijn GH van Oijen

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

Mirthe E. van der Valk, Marie‐Josée J. Mangen, Max Leenders et al. · Gut · 2012 · 498 citations · Full text

Pharmacy, Pharmacoeconomics, Surgery +17

Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial

Corine J. van Marrewijk, Suhreta Mujakovic, Gerdine A. J. Fransen et al. · The Lancet · 2009 · 82 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +11

Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma

Jón Kristinsson, Paul van Westerveld, René HM te Morsche et al. · World Journal of Gastroenterology · 2009 · 39 citations · Full text

Medicine, Genetics, Oncology +14

Risk of post‐colonoscopy colorectal cancer due to incomplete adenoma resection: A nationwide, population‐based cohort study

Tim D. Belderbos, Hendrikus J.M. Pullens, Max Leenders et al. · United European Gastroenterology Journal · 2016 · 27 citations · Full text

Medicine, Oncology, Pathology +17

An assisted structured reflection on life events and life goals in advanced cancer patients: Outcomes of a randomized controlled trial (Life InSight Application (LISA) study)

Renske Kruizinga, Michael Scherer‐Rath, Johannes BAM Schilderman et al. · Palliative Medicine · 2018 · 19 citations · Full text

Medicine, Oncology, Palliative Care +16